Long-term treatment outcome with different formulations of botulinum toxin

Eur J Neurol. 2009 Mar;16(3):285-6. doi: 10.1111/j.1468-1331.2008.02508.x.
No abstract available

Publication types

  • Comment
  • Editorial

MeSH terms

  • Acetylcholine / metabolism
  • Animals
  • Anti-Dyskinesia Agents / adverse effects
  • Anti-Dyskinesia Agents / pharmacology
  • Anti-Dyskinesia Agents / therapeutic use*
  • Botulinum Toxins / adverse effects
  • Botulinum Toxins / pharmacology
  • Botulinum Toxins / therapeutic use*
  • Botulinum Toxins, Type A / adverse effects
  • Botulinum Toxins, Type A / pharmacology
  • Botulinum Toxins, Type A / therapeutic use
  • Drug Resistance
  • Dyskinesias / drug therapy*
  • Humans
  • Neuromuscular Junction / drug effects
  • Neuromuscular Junction / metabolism
  • Treatment Outcome

Substances

  • Anti-Dyskinesia Agents
  • Botulinum Toxins
  • Botulinum Toxins, Type A
  • Acetylcholine